

Ajanta House Charkop, Kandivli West, Mumbai 400 067

F +91 22 6606 1200 E legal.info@ajantapharma.com W www.ajantapharma.com

T +91 22 6606 1000

5th May 2023

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Exchange Plaza, 5th Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 31st March 2023.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary

Encl.: a/a

Rs. (in crs)

													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter- deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once the reporting period when such transaction was undertaken.										
	Details of the pa entity /subs entering in transact	sidiary) ito the	Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the	e loans, inter-o	corporate dep	osits, advance	s or investments	Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee			Opening balance	Closing balance	Nature of indebtednes s (loan/ issuance of debt/ any other etc.)	Details of other indebtednes s	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
1	Ajanta Pharma Limted		Ajanta Foundation		Company is able to exercise significant control over this entity	Any other transaction	Corporate Social Responsibility expense	1.00	Transactions are carried out on arms length basis and in ordinary course of business	0.15	0	C	0										
2	Ajanta Pharma Limted		M/s. Al Packaging		Relative of Chairman	Purchase of goods or services		10.00	Transactions are carried out on arms length basis and in ordinary course of business	4.23	0	C	0										
3	Ajanta Pharma Limted		M/s. Al Packaging		Relative of Chairman	Any other transaction	Trade Payable		N.A.	0	0.68	0.78	8										
4	Ajanta Pharma Limted		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Sale of goods or services		75.00	Transactions are carried out on arms length basis and in ordinary course of business	24.95	0	C	0										
5	Ajanta Pharma Limted		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Any other transaction	Trade Receivables		N.A.	0	28.25	22.56	6										
6	Ajanta Pharma Limted		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Any other transaction	Trade Payable		N.A.	0	0	C	D C										
7	Ajanta Pharma Limted		Ajanta Pharma Limited Group Gratuity Trust		Company is able to exercise significant control over this entity	Any other transaction	Contribution to employment benefit plans		N.A.	0.38	0	C	0										
8	Ajanta Pharma Limted		Ajanta Pharma Nigeria Ltd		Subsidiary	Any other transaction	Reimbursement of expenses		N.A.	0.23	0	C	0										
9	Ajanta Pharma Limted		Ajanta Pharma Nigeria Ltd		Subsidiary	Any other transaction	Advance Given		N.A.	0	0.06	0.04	4										
10	Ajanta Pharma Limted		Ajanta Pharma Philippines Inc.		Subsidiary	Sale of goods or services		170.00	Transactions are carried out on arms length basis and in ordinary course of business	91.4	0	C	0										
11	Ajanta Pharma Limted		Ajanta Pharma Philippines Inc.		Subsidiary	Any other transaction	Trade Receivables		N.A.	O	39.66	43.3	3										
12	Ajanta Pharma Limted		Ajanta Pharma Philippines Inc.		Subsidiary	Investment			N.A.	0	1.38	1.38	8									 	
13	Ajanta Pharma Limted		Ajanta Pharma USA Inc.		Subsidiary	Sale of goods or services		600.00	Transactions are carried out on arms length basis and in ordinary course of business	413.12	0	C	0										

Relate	Details of the party (listed Details of the counterparty Type of related Details of other Value of the Remarks on approval by audit Value of In case monies are due to													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only one the reporting period when such transaction was undertaken.										
Sr No.	r No. Details of the party entity /subsidia entering into t transaction		idiary) to the			Details of other related party transaction	Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	either party as a result of the transaction		1				Details of the	loans, inter-	corporate dep	osits, advance	s or investments	Notes			
	Name	PAN	Name	PAN Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee			Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtednes s	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)				
14	Ajanta Pharma Limted		Ajanta Pharma USA Inc.	Subsidiary	Any other transaction	Other Income	1.50	Transactions are carried out on arms length basis and in ordinary course of business	0.62	0	C	0												
	Ajanta Pharma Limted		Ajanta Pharma USA Inc.	Subsidiary	Any other transaction	Trade Receivables		N.A.	0	642.27	568.8													
16	Ajanta Pharma Limted		Ajanta Pharma USA	Subsidiary	Any other transaction	Other Receivables		N.A.	0	1.05	0.62	2									İ			
17	Ajanta Pharma Limted		Ajanta Pharma USA Inc.	Subsidiary	Investment			N.A.	0	7.07	7.07	7												
18	Ajanta Pharma Limted		Arvind Agrawal	Chief Financial Officer & KMP	Any other transaction	Short Term Employee benefits		N.A.	0.82	0	C	0												
19	Ajanta Pharma Limted		Arvind Agrawal	Chief Financial Officer & KMP	Any other transaction	Post Employment Benefits		N.A.	0	0	C	D												
20	Ajanta Pharma Limted		Chandrakant M. Khetan	Independent Director	Any other transaction	Sitting fees paid		N.A.	0.04	. 0	C	0												
21	Ajanta Pharma		Chandrakant M.	Independent Director	Any other	Commission to		N.A.	0.02	0	C	0												
22	Limted Ajanta Pharma Limted		Khetan Chandrakant M. Khetan	Independent Director	transaction Any other transaction	Directors Commission payable		N.A.	0	0.02	0.04	4												
23	Ajanta Pharma Limted		Dr. Anjana Grewal	Independent Director		Sitting fees paid		N.A.	0.03	0	C	D												
24	Ajanta Pharma Limted		Dr. Anjana Grewal	Independent Director	Any other transaction	Commission to Directors		N.A.	0.02	0	C	0												
25	Ajanta Pharma Limted		Dr. Anjana Grewal	Independent Director	Any other transaction	Commission payable		N.A.	0	0.012	0.03	3												
26	Ajanta Pharma Limted		Gaurang Shah	Company Secretary & KMP	Any other transaction	Short Term Employee benefits		N.A.	0.46	0	C	0												
27	Ajanta Pharma Limted		Gaurang Shah	Company Secretary & KMP	Any other transaction	Post Employment Benefits		N.A.	0	0	C	0												
28	Ajanta Pharma Limted		K. H. Viswanathan	Independent Director	Any other transaction	Sitting fees paid		N.A.	0.04	0	(0												
	Ajanta Pharma Limted		K. H. Viswanathan	Independent Director	Any other transaction	Commission to Directors		N.A.	0.02		(0												
30	Ajanta Pharma Limted		K. H. Viswanathan	Independent Director	Any other transaction	Commission payable		N.A.	0	0.0121	0.03	3									1			
31	Ajanta Pharma Limted		Madhusudan B. Agrawal	Executive Vice-Chairman	Any other transaction	Short Term Employee benefits		N.A.	1.72	0	C	0												

Rs. (in crs)

Kelated	No. Details of the party (listed Details of the counterparty Type of related Details of other Value of the Remarks on approval by audit Value of In case monies are due to												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inte deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only or the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of	the counterparty	Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		make or g	financial indebtedness i ive loans, inter-corporat advances or investment	Details of the	loans, inter-	corporate dep	osits, advances	s or investments	Notes				
	Name	PAN	Name PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee			Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of cost other indebtednes s	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)				
32	Ajanta Pharma Limted		Madhusudan B. Agrawal	Executive Vice-Chairman	Any other transaction	Post Employment Benefits		N.A.	0	C		D											
33	Ajanta Pharma Limted		Mamta and Madhusudan Agrawal Memorial Foundation	Promoter group is able to exercise significant control over this entity	Any other r transaction	Corporate Social Responsibility expense	5.35	Transactions are carried out on arms length basis and in ordinary course of business	3.25	C)											
34	Ajanta Pharma Limted		Mannalal B. Agrawal	Non Executive Director - Chairman	Any other transaction	Sitting fees paid		N.A.	0.04	С	,									 I			
35	Ajanta Pharma Limted		Prabhakar Dalal	Independent Director	Any other transaction	Sitting fees paid		N.A.	0.03	С	(D								1			
36	Ajanta Pharma Limted		Prabhakar Dalal	Independent Director	Any other transaction	Commission to Directors		N.A.	0.02	С	(D								1			
37	Ajanta Pharma Limted		Prabhakar Dalal	Independent Director	Any other transaction	Commission payable		N.A.	0	0.0121	0.03	3								I			
38	Ajanta Pharma Limted		Rajesh M. Agrawal	Joint Managing Director & KMP	Any other transaction	Short Term Employee benefits		N.A.	6.17	C	()											
39	Ajanta Pharma Limted		Rajesh M. Agrawal	Joint Managing Director & KMP	Any other transaction	Post Employment Benefits		N.A.	0.04	C	()											
40	Ajanta Pharma Limted		Rajesh M. Agrawal	Joint Managing Director & KMP	Any other transaction	Commission to Directors		N.A.	0.68	С		D											
41	Ajanta Pharma Limted		Rajesh M. Agrawal	Joint Managing Director & KMP	Any other transaction	Commission payable	!	N.A.	0	2.63	3.3	3											
42	Ajanta Pharma Limted		Seth Bhagwandas Agarwal Charitable Trust	Promoter group is able to exercise significant control over this entity	Any other r transaction	Corporate Social Responsibility expense	1.00	Transactions are carried out on arms length basis and in ordinary course of business	0	C		0											
43	Ajanta Pharma Limted		Tanya Agrawal	Daughter of Managing Director	Any other transaction	Short Term Employee benefits		Transactions are carried out on arms length basis and in ordinary course of business	0.05	C	(D											
44	Ajanta Pharma Limted		Tanya Agrawal	Daughter of Managing Director	Any other transaction	Post Employment Benefits		N.A.	0	C		0											
45	Ajanta Pharma Limted		Yogesh M. Agrawal	Managing Director & KMP	Any other transaction	Short Term Employee benefits		N.A.	6.17	С	(D											

,	d party transactio													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter- deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only onc the reporting period when such transaction was undertaken.									
or No. Details of the pentity /subentering in transac		diary) o the	d Details of the counterparty			Type of related party transaction		Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		make or g	financial indeb ive loans, inter advances or in	r-corporat	e deposits,	Details of the	loans, inter-	corporate dep	osits, advance	s or investments	Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee			Opening balance	Closing balance	Nature of indebtednes s (loan/ issuance of debt/ any other etc.)	Details of other indebtednes s	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
46	Ajanta Pharma Limted		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Post Employment Benefits		N.A.	0.04	0	(0										
47	Ajanta Pharma Limted		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Commission to Directors		N.A.	0.68	0	(0										
48	Ajanta Pharma Limted		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Commission payable		N.A.	0	2.63	3.3	3										
49	Ajanta Pharma Limted		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Investment			N.A.	0	9.44	9.44	4										
50	Ajanta Pharma Limted		Ajanta Pharma Philippines Inc.		Subsidiary	Dividend received			N.A.	0	0	(0									ĺ	
51	Ajanta Pharma Limted		Samta Puroshattam Agrawal Memorial Foundation		Promoter group is able to exercise significant control over this entity	Any other	corporate Social Responsibility expense	5.75	Transactions are carried out on arms length basis and in ordinary course of business	2.94	0	(0										
52	Ajanta Pharma Limted		Manisha Yogesh Agrawal foundation		promoter group is able to exercise significant control over this entity	Any other transaction	Corporate Social Responsibility expense		Transactions are carried out on arms length basis and in ordinary course of business	0.25	0	(0										
53	Ajanta Pharma Limted		Yogesh M Agrawal, trustee Yogesh Agrawal Trust		Promoter	Dividend paid			N.A.	13	0	(0										
54	Ajanta Pharma Limted		Rajesh M Agrawal, trustee Rajesh Agrawal Trust		Promoter	Dividend paid			N.A.	13	0	(0										
55	Ajanta Pharma Limted		Ravi P Agrawal, trustee Ravi Agrawal Trust		Promoter	Dividend paid			N.A.	12.89	0	(0										
56	Ajanta Pharma Limted		Ravi P Agrawal		Promoter	Dividend paid			N.A.	0.2	0	(0										
57	Ajanta Pharma Limted		Aayush M Agrawal, trustee Aayush Agrawal Trust		Promoter	Dividend paid			N.A.	12.87	0	(0										
58	Ajanta Pharma Limted		Aayush M Agrawal		Promoter	Dividend paid			N.A.	0.02	0	(0										
59	Ajanta Pharma Limted		Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal		Promoter	Dividend paid			N.A.	2.41	0	(0										

	d party transactio	-											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-cc deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, the reporting period when such transaction was undertaken.										
ir No. Details of the party (listed entity /subsidiary) entering into the transaction	ed Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		■				Details of the	e loans, inter-	corporate dep	osits, advance	s or investments	Notes			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary			by the audit committee			Opening balance	Closing balance	Nature of indebtednes s (loan/ issuance of debt/ any other etc.)	Details of other indebtednes s	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure		Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
60	Ajanta Pharma		Gabs Investments		Promoter	Dividend paid			N.A.	8.81	0	C)										
	Limted		Pvt Ltd																				
61	Ajanta Pharma Limted		Arvind Agrawal		Chief Financial Officer & KMP	Dividend paid			N.A.	0.03	0	C)									-	
62	Ajanta Pharma Limted		Gaurang Shah		Company Secretary & KMP	Dividend paid			N.A.	0	0	C											
63	Ajanta Pharma Limted		Chandrakant Khetan		Independent Director	Dividend paid			N.A.	0	0	C											
64	Ajanta Pharma Limted		Yogesh M Agrawal, trustee Yogesh Agrawal Trust		Promoter		Buyback of Equity Shares		N.A.	48.07	0	C											
65	Ajanta Pharma Limted		Rajesh M Agrawal, trustee Rajesh Agrawal Trust		Promoter		Buyback of Equity Shares		N.A.	48.07	0	C	1										
66	Ajanta Pharma Limted		Ravi P Agrawal, trustee Ravi Agrawal Trust		Promoter		Buyback of Equity Shares		N.A.	43.28	0	C											
67	Ajanta Pharma Limted		Aayush M Agrawal, trustee Aayush Agrawal Trust		Promoter		Buyback of Equity Shares		N.A.	39.34	0	C											
68	Ajanta Pharma Limted		Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal		Promoter	Any other transaction	Buyback of Equity Shares		N.A.	10.04	0	C											
69	Ajanta Pharma Limted		Arvind Agrawal		Chief Financial Officer & KMP	Any other transaction	Buyback of Equity Shares		N.A.	0.11	0	C											
70	Ajanta Pharma Limted		Gaurang Shah		Company Secretary & KMP		Buyback of Equity Shares		N.A.	0	0	C										-	
71	Ajanta Pharma Limted		Chandrakant Khetan		Independent Director		Buyback of Equity Shares		N.A.	0	0	C)										
tal v		on during t	he reporting period	1		ti ai isaction	Jilaies			810.75	ı		1	1		1	1		l				

Note

¹⁾ Amount approved by Audit Committee is for the entire financial year.

²⁾ As per Regulation 23(5) of the SEBI (LODR) Regulation 2015, transactions entered into between a holding company and its wholly owned subsidiary whose accounts are consolidated with such holding company and placed before the shareholders at the general meeting for approval do not require prior approval of Audit Committee. Hence for transactions with all the wholly owned subsidiaries like dividend received, investments, trade and other receivables etc. at Sr. No. 5 to 9, 11, 12, 15 to 17, 49 and 50 (save and except for sale /purchase of goods), audit committee approval is not sought.

³⁾Transactions at Sr. No. 3, 18 to 32, 34 to 41, 43 to 48 and 53 to 71 pertaining to payment of dividend to promoters, contribution to gratuity trust, remuneration of Directors, their relatives & KMPs, Director's sitting fees, buyback of shares etc. are at actuals and approval of Board was taken for the same.